Loading
A phase 1/2 trial of Inobrodib run by CellCentric Ltd., completed.
Study to Evaluate CCS1477 in Advanced Tumours is a phase 1/2 interventional study registered as NCT03568656 by CellCentric Ltd., with 219 participants enrolled, started 2018-07-23, primary completion reached 2025-07-06. Conditions recorded: Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors. Interventions recorded: CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab.
Shares Inobrodib, CellCentric and the tag pipeline.
Shares Inobrodib, CellCentric and the tag pipeline.
Shares Inobrodib, CellCentric.
Shares Inobrodib, CellCentric.
Shares Inobrodib, CellCentric.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/